keyword
MENU ▼
Read by QxMD icon Read
search

cirrhosis, hepatitis c, HCC

keyword
https://www.readbyqxmd.com/read/28647765/epidemiology-of-hepatocellular-carcinoma-target-population-for-surveillance-and-diagnosis
#1
REVIEW
An Tang, Oussama Hallouch, Victoria Chernyak, Aya Kamaya, Claude B Sirlin
Hepatocellular carcinoma (HCC) is the sixth most common cancer and the second leading cause of cancer mortality worldwide. Incidence rates of liver cancer vary widely between geographic regions and are highest in Eastern Asia and sub-Saharan Africa. In the United States, the incidence of HCC has increased since the 1980s. HCC detection at an early stage through surveillance and curative therapy has considerably improved the 5-year survival. Therefore, medical societies advocate systematic screening and surveillance of target populations at particularly high risk for developing HCC to facilitate early-stage detection...
June 24, 2017: Abdominal Radiology
https://www.readbyqxmd.com/read/28642869/detection-of-microrna-in-hepatic-cirrhosis-and-hepatocellular-carcinoma-in-hepatitis-c-genotype-4-in-egyptian-patients
#2
Hala M Demerdash, Hend M Hussien, Ehab Hassouna, Emad A Arida
BACKGROUND: In Egypt, the prevalence of chronic hepatitis C (CHC) infection is 13.8% of whole population and about 80% of the patients with hepatocellular carcinoma have underling hepatitis C. AIM: This study was designed to assess the diagnostic value of plasma miR-122 and miR-21 in patients with CHC, genotype-4, to detect fibrosis progression versus noninvasive indices and their diagnostic value in detection of early stages of hepatocellular carcinoma (HCC). METHODOLOGY: A prospective study that included 180 patients, divided into 3 groups: healthy controls (group I), CHC patients (group II), and hepatitis C patients with HCC (group III); all cases were subjected to thorough clinical, radiological, and laboratory investigations...
2017: BioMed Research International
https://www.readbyqxmd.com/read/28640517/hepatocellular-carcinoma-in-south-america-evaluation-of-risk-factors-demographics-and-therapy
#3
Jose D Debes, Aaron J Chan, Domingo Balderramo, Luciana Kikuchi, Esteban Gonzalez Ballerga, Jhon E Prieto, Monica Tapias, Victor Idrovo, Milagros B Davalos, Fernando Cairo, Fernando J Barreyro, Sebastian Paredes, Nelia Hernandez, Karla Avendaño, Javier Diaz Ferrer, Ju Dong Yang, Enrique Carrera, Jairo A Garcia, Angelo Z Mattos, Bruno S Hirsch, Pablo T Gonçalves, Flair J Carrilho, Lewis R Roberts
BACKGROUND AND AIMS: Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide. Most studies addressing the epidemiology of HCC originate from developed countries. This study reports the preliminary findings of a multinational approach to characterize HCC in South America. METHODS: We evaluated 1336 HCC patients seen at 14 centers in six South American countries using a retrospective study design with participating centers completing a template chart of patient characteristics...
June 22, 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/28633200/complete-response-of-advanced-hepatocellular-carcinoma-to-sorafenib-another-case-and-a-comprehensive-review
#4
Tae Suk Kim, Ji Hoon Kim, Baek Hui Kim, Young-Sun Lee, Yang Jae Yoo, Seong Hee Kang, Sang-June Suh, Young Kul Jung, Yeon Seok Seo, Hyung Joon Yim, Jong Eun Yeon, Kwan Soo Byun
Since sorafenib was introduced in 2007 for treating advanced hepatocellular carcinoma (HCC), 15 patients have achieved a complete response (CR) in advanced HCC. However, only four of these reports can be regarded as real CRs involving adequate assessments including imaging, serum tumor markers, and histologic examinations of completely resected specimens. A 54-year-old man with hepatitis C virus (HCV)-related liver cirrhosis (LC) presented to our unit. A CT scan demonstrated a 3.8-cm arterial hypervascular/portal-washout mass in the right lobe and invasion in the right portal vein...
June 20, 2017: Clinical and Molecular Hepatology
https://www.readbyqxmd.com/read/28626882/quantitative-proteome-analysis-of-plasma-microparticles-for-the-characterization-of-hcv-induced-hepatic-cirrhosis-and-hepatocellular-carcinoma
#5
Raghda Saad Zaghloul Taleb, Pacint Moez, Doreen Younan, Martin Eisenacher, Matthias Tenbusch, Barbara Sitek, Thilo Bracht
Hepatocellular carcinoma (HCC) is the most common primary malignant liver tumor and a leading cause of cancer-related deaths worldwide. Cirrhosis induced by hepatitis-C virus (HCV) infection is the most critical risk factor for HCC. However, the mechanism of HCV-induced carcinogenesis is not fully understood. Plasma microparticles (PMP) contribute to numerous physiological and pathological processes and contain proteins whose composition correlates to the respective pathophysiological conditions. Given this fact, we analyzed PMP from 22 HCV-induced cirrhosis patients, 16 HCV-positive HCC patients with underlying cirrhosis and 18 healthy controls...
June 19, 2017: Proteomics. Clinical Applications
https://www.readbyqxmd.com/read/28623331/clinical-efficacy-and-post-treatment-seromarkers-associated-with-the-risk-of-hepatocellular-carcinoma-among-chronic-hepatitis-c-patients
#6
Mei-Hsuan Lee, Chung-Feng Huang, Hsueh-Chou Lai, Chun-Yen Lin, Chia-Yen Dai, Chun-Jen Liu, Jing-Houng Wang, Jee-Fu Huang, Wen-Pang Su, Hung-Chih Yang, Kwong-Ming Kee, Ming-Lun Yeh, Po-Heng Chuang, Shih-Jer Hsu, Ching-I Huang, Jung-Ta Kao, Chieh-Chang Chen, Sheng-Hung Chen, Wen-Juei Jeng, Hwai-I Yang, Yong Yuan, Sheng-Nan Lu, I-Shyan Sheen, Chen-Hua Liu, Cheng-Yuan Peng, Jia-Horng Kao, Ming-Lung Yu, Wan-Long Chuang, Chien-Jen Chen
This follow-up study enrolled chronic hepatitis C patients to evaluate the treatment efficacy and to identify post-treatment seromarkers associated with risk of hepatocellular carcinoma (HCC) among patients with a sustained virological response (SVR) or nonsustained virological response (NSVR). A total of 4639 patients who received pegylated interferon and ribavirin during 2004-2013 were followed until December 2014. HCC was confirmed through health examinations and data linkage with a national database. A total of 233 HCC cases were reported after 26,163 person-years of follow-up, indicating an incidence of 8...
June 16, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28621554/gut-microbiota-changes-and-chronic-hepatitis-c-virus-infection
#7
Tomislav Preveden, Emidio Scarpellini, Natasa Milić, Francesco Luzza, Ludovico Abenavoli
Hepatitis C virus (HCV) infection is a global health problem with 150 million infected people worldwide. Liver can be greatly affected by changes in gut microbiota due to increased intestinal permeability with passage of microbial antigens into the liver through the portal circulation. The concept of "gut-liver" axis is important to understand the pathophysiology of several liver diseases. Several recent studies also revealed that an altered gut microbiota can be implicated in the pathogenesis of HCV-induced chronic liver disease (CHC)...
June 16, 2017: Expert Review of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28619403/practice-knowledge-and-barriers-for-screening-of-hepatocellular-carcinoma-among-high-risk-chinese-patients
#8
Kerui Xu, Shinobu Watanabe-Galloway, Fedja A Rochling, Jianjun Zhang, Paraskevi A Farazi, Hongyan Peng, Hongmei Wang, Jiangtao Luo
BACKGROUND: Hepatocellular carcinoma (HCC) is among the leading causes of cancer deaths in China. Considering its poor prognosis when diagnosed late, Chinese guidelines recommend biannual screening for HCC with abdominal ultrasound and serum α-fetoprotein (AFP) test for high-risk populations. OBJECTIVES: To investigate the practice, knowledge, and self-perceived barriers for HCC screening among high-risk hospital patients in China. METHODS: An interview-based questionnaire was conducted among Chinese patients with chronic hepatitis B and/or chronic hepatitis C infection from outpatient clinics at 2 tertiary medical institutions in Shanghai and Wuhan, China...
March 2017: Annals of Global Health
https://www.readbyqxmd.com/read/28611258/independent-predictors-of-mortality-and-resource-utilization-in-viral-hepatitis-related-hepatocellular-carcinoma
#9
Pegah Golabi, Thomas Jeffers, Zahra Younoszai, Munkhzul Otgonsuren, Mehmet Sayiner, Alita Mishra, Chapy Venkatesan, Zobair Younossi
INTRODUCTION: Hepatitis B (HBV) and C viruses (HCV) are important causes of hepatocellular carcinoma (HCC). Our aim was to assess mortality and resource utilization of patients with HCC-related to HBV and HCV. MATERIAL AND METHODS: National Cancer Institute's Surveillance, Epidemiology and End Results (SEER)-Medicare linked database (2001-2009) was used. Medicare claims included patient demographic information, diagnoses, treatment, procedures, ICD-9 codes, service dates, payments, coverage status, survival data, carrier claims, and Medicare Provider Analysis and Review (MEDPAR) data...
August 1, 2017: Annals of Hepatology
https://www.readbyqxmd.com/read/28609212/correlation-of-serum-soluble-fibrinogen-like-protein-2-with-soluble-fas-ligand-and-interferon-gamma-in-egyptian-hepatitis-c-virus-infected-patients-and-hepatocellular-carcinoma-patients
#10
Mohamed El-Mesery, Mohammed El-Mowafy, Abdelaziz Elgaml, Laila F Youssef, Sally Y Abed
Infection with hepatitis C virus (HCV) remains one of the serious human diseases worldwide, especially in Egypt, which can lead to cirrhosis or hepatocellular carcinoma (HCC). However, the exact molecular mechanism of HCC progress in HCV-infected patients remains unclear. Soluble fibrinogen-like protein 2 (sFGL2) is a modulator of the immune response that is secreted by T cells and inhibits maturation of dendritic cells and T cell proliferation. In the current study, serum sFGL2 levels were analyzed by enzyme-linked immunosorbent assay (ELISA) technique in 30 chronic HCV-infected patients (HCV group), 30 chronic HCV-infected patients with HCC (HCC group), and 12 healthy individuals (control group)...
June 13, 2017: Journal of Interferon & Cytokine Research
https://www.readbyqxmd.com/read/28595541/evaluating-the-role-of-interleukin-12-b-gene-polymorphism-in-prediction-of-disease-progression-in-patients-with-chronic-hepatitis-c-virus-infection
#11
Nadia Elwan, Khalda Amr, Sahar Elyamany, Walaa Elkhalawany, Shaimaa Soliman, Mohamed Ziada, Sherief Abd-Elsalam
Background &Aims: Cell-mediated immunity plays a critical role in viral clearance and disease progression during Hepatitis C virus (HCV) infection. Interleukin (IL)-12 is a cytokine that has been shown to be a potent antiviral cytokine. The aim of this work is to investigate the association of IL-12 B gene polymorphism with the progression of liver disease in chronic HCV patients. METHODS: This cross sectional study was carried out in tropical medicine department, Tanta university hospital, Egypt, on 120 chronic HCV patients with various stages of liver disease and 30 healthy subjects served as control...
June 5, 2017: Infectious Disorders Drug Targets
https://www.readbyqxmd.com/read/28592127/methylation-of-sox1-and-vim-promoters-in-serum-as-potential-biomarkers-for-hepatocellular-carcinoma
#12
X Y Liu, Y C Fan, S Gao, J Zhao, L Y Chen, F Li, K Wang
Aberrant methylation of tumor-related genes has been identified as a promising biomarker for hepatocellular carcinoma (HCC). This study aimed to investigate the diagnostic value of SRY (sex determining region Y)-box 1 (SOX1) and Vimentin (VIM) promoter methylation for HCC. The study included 360 subjects, 240 patients with HCC, 29 with liver cirrhosis (LC), 66 with chronic hepatitis B (CHB) and 25 healthy controls (HCs). The methylation status of SOX1 and VIM promoters in the serum was detected by methylation-specific polymerase chain reaction (MSP)...
June 8, 2017: Neoplasma
https://www.readbyqxmd.com/read/28591560/implications-of-the-lysophosphatidic-acid-signaling-axis-in-liver-cancer
#13
REVIEW
Chiara Lopane, Pasquale Agosti, Isabella Gigante, Carlo Sabbà, Antonio Mazzocca
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death in western countries. The major risk factors for HCC are hepatitis C or B viruses, alcohol and metabolic disorders. The increasing risk of HCC in patients with metabolic disorders (i.e. obesity, diabetes and non-alcoholic steatohepatitis/NASH) regardless of the presence of liver cirrhosis is becoming relevant. Nevertheless, molecular mechanisms linking these risk factors to liver oncogenesis are unclear. This review focuses on the pathogenic role of the lysophosphatidic acid (LPA) pathway in HCC, highlighting the implications of this bioactive phospholipid in liver cancer biology and metabolism and as potential therapeutic target...
June 4, 2017: Biochimica et Biophysica Acta
https://www.readbyqxmd.com/read/28566078/-determination-of-drug-resistance-mutations-of-ns3-inhibitors-in-chronic-hepatitis-c-patients-infected-with-genotype-1
#14
Tamer Şanlıdağ, Murat Sayan, Sinem Akçalı, Elmas Kasap, Tahir Buran, Ayşe Arıkan
Direct-acting antiviral agents (DAA) such as NS3 protease inhibitors is the first class of drugs used for chronic hepatitis C (CHC) treatment. NS3 inhibitors (PI) with low genetic barrier have been approved to be used in the CHC genotype 1 infections, and in the treatment of compensated liver disease including cirrhosis together with pegile interferon and ribavirin. Consequently, the development of drug resistance during DAA treatment of CHC is a major problem. NS3 resistant variants can be detected before treatment as they can occurnaturally...
April 2017: Mikrobiyoloji Bülteni
https://www.readbyqxmd.com/read/28562104/liver-cirrhosis-stages-and-the-incidence-of-hepatocellular-carcinoma-in-chronic-hepatitis-b-patients-receiving-antiviral-therapy
#15
Jae-Jun Shim, Chi Hyuck Oh, Jung Wook Kim, Chang Kyun Lee, Byung-Ho Kim
OBJECTIVES: Long-term antiviral therapy decreases the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB), however, it cannot eliminate the risk. We investigated the incidence of HCC at different stages of liver cirrhosis (LC) and identified clinical predictors for HCC development during antiviral therapy. METHODS: The data from 356 treatment-naïve patients aged 40 to 69 years without a history of HCC who had received entecavir for ≥6 months were collected retrospectively...
May 31, 2017: Scandinavian Journal of Gastroenterology
https://www.readbyqxmd.com/read/28547948/cytokeratin-18-in-diagnosis-of-hcc-in-patients-with-liver-cirrhosis
#16
Saber A Ismail, Sherif El Saadany, Dina H Ziada, Soha S Zakaria, Wael W Mayah, Heba Elashry, Mona Arafa, Nehal Elmashad
Background: Hepatocellular carcinoma (HCC) is a common malignancy that occurs secondary to viral hepatitis B and C cirrhosis under the influence of environmental factors. In early stages, clinical diagnosis is often difficult and distinguishing HCC from cirrhosis and other hepatic masses by conventional tests is frequently not feasible. Physicians usually depend on measuring serum alpha-fetoprotein (AFP), but this marker has low sensitivity and specificity. The aim of this research was to determine any role of serum cytokeratin-18(Ck-18) as a marker for diagnosis of HCC in patients with liver cirrhosis...
April 1, 2017: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/28544696/increased-incidence-of-liver-cancer-after-successful-daa-treatment-of-chronic-hepatitis-c-fact-or-fiction
#17
Alfredo Alberti, Sara Piovesan
Therapy of hepatitis C has been revolutionized by Direct Antiviral Agents. These drugs are safe and efficacious in all infected patients, including those with advanced, or decompensated cirrhosis, and are currently largely used in such cases in clinical practice worldwide. It was therefore cause of great concern the publication of two reports suggesting that treatment with DAAs could increase the risk of hepatocellular carcinoma in cirrhotic patients, particularly in those receiving antiviral therapy after having been cured for an HCC...
June 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/28543911/polymorphism-of-tlr5-rs5744174-is-associated-with-disease-progression-in-chinese-patients-with-chronic-hbv-infection
#18
Lina Cao, Tong Zhang, Junping Zhu, Aixin Li, Kai Zheng, Nan Zhang, Bin Su, Wei Xia, Hao Wu, Ning Li, Qiushui He
Toll-like receptors (TLRs) play a crucial role in innate and adaptive immunity, protecting the host from viral pathogens. Studies have implicated that TLR5 is associated with various diseases such as autoimmune and inflammation related diseases. However, little is known about the relationship between TLR5 and hepatitis B virus (HBV) infection. We studied the effect of TLR5 gene polymorphisms on susceptibility to and disease progression of chronic hepatitis B (CHB) infection in Chinese. Blood samples were taken from 636 patients with CHB, HBV-related liver cirrhosis (LC) or hepatocellular carcinoma (HCC) and 273 controls...
May 25, 2017: APMIS: Acta Pathologica, Microbiologica, et Immunologica Scandinavica
https://www.readbyqxmd.com/read/28521452/assessment-of-high-sensitivity-c-reactive-protein-tests-for-the-diagnosis-of-hepatocellular-carcinoma-in-patients-with-hepatitis-b-associated-liver-cirrhosis
#19
Li-Na Ma, Xiao-Yan Liu, Zhen-Hui Lu, Li-Gang Wu, Yuan-Yuan Tang, Xia Luo, Yan-Chao Hu, Ting-Ting Yan, Qi Wang, Xiang-Chun Ding, Yan Xie
Hepatocellular carcinoma (HCC) is a common malignant tumor worldwide, with high morbidity and mortality. Chronic infection with hepatitis B virus (HBV) is a major risk factor for the development of hepatocellular carcinoma and the majority (~80%) of hepatocellular carcinoma patients in China exhibit co-morbidity with HBV-associated liver cirrhosis. The goal of reliable early diagnostic and prognostic techniques for HBV-associated HCC remains unrealized. The aim of the present study was to explore the efficacy of serum high-sensitivity C-reactive protein (hs-CRP) tests in the early diagnosis of HCC in patients with HBV-associated liver cirrhosis...
May 2017: Oncology Letters
https://www.readbyqxmd.com/read/28520728/cost-effectiveness-of-hepatitis-c-treatment-using-generic-direct-acting-antivirals-available-in-india
#20
Rakesh Aggarwal, Qiushi Chen, Amit Goel, Nicole Seguy, Razia Pendse, Turgay Ayer, Jagpreet Chhatwal
BACKGROUND & AIMS: Availability of directly-acting antivirals (DAAs) has changed the treatment landscape of hepatitis C virus (HCV) infection. The high price of DAAs has restricted their use in several countries. However, in some countries such as India, generic DAAs are available at much cheaper price. This study examined whether generic DAAs could be cost-saving and how long it would take for the treatment to become cost-saving/effective. METHODS: A previously-validated, mathematical model was adapted to the HCV-infected population in India to compare the outcomes of no treatment versus treatment with DAAs...
2017: PloS One
keyword
keyword
116431
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"